Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | PRKCA | P17252 | 4/20 | 0.36 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.36 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28506196 | 1.00 | CTSK (0.42) | CTSKMAPK1MAPTCA2CA1 | |
| SCHEMBL29093874 | 1.00 | CTSK (0.42) | CTSKMAPK1MAPTCA2CA1 | |
| SCHEMBL27812361 | 0.90 | CTSK (0.41) | CTSKMAPK1MAPTCA2CA1 | |
| SCHEMBL27832487 | 0.90 | CTSK (0.41) | CTSKMAPK1MAPTCA2CA1 | |
| SCHEMBL28531110 | 0.89 | CTSK (0.44) | CTSKMAPK1MAPTCA2CA1 | |
| SCHEMBL29187868 | 0.88 | CTSK (0.54) | CTSKMAPK1CA2CA1 | |
| SCHEMBL27696914 | 0.85 | CPB2 (0.34) | MAPK1MAPTPRKCA | |
| SCHEMBL28710858 | 0.85 | PRKCA (0.33) | CTSKMAPK1MAPTPRKCA | |
| SCHEMBL27542784 | 0.83 | CTSK (0.45) | CTSKMAPK1CA2CA1PRKCA | |
| SCHEMBL28670288 | 0.83 | PRKCA (0.36) | PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216787-A1 | THIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-26 | — | — | US | disclosed |
| US-7678810-B2 | Thiazole derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2010-03-16 | — | — | US | disclosed |
| US-20070154428-A1 | Thiazole derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1721905-A1 | THIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216787-A1 | THIAZOLE DERIVATIVE | TGFBR1, TGFBR2, SMAD3 | CTSK 3645/4885MAPK1 297/4885MAPT 3312/4885 |
| US-20070154428-A1 | Thiazole derivative | TGFBR1, TGFBR2, SMAD3 | CTSK 3645/4885MAPK1 297/4885MAPT 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.